Tag: 300-400

An application of continuous flow microreactor in the synthesis and extraction of rabeprazole was written by Duan, Zhenya;Wang, Yan;Zhang, Ling;Cao, Xing;Fu, Lihua;Li, Zhenjiang;Zhang, Junmei. And the article was included in International Journal of Chemical Reactor Engineering in 2021.Category: imidazoles-derivatives The following contents are mentioned in the article:

The oxidation of rabeprazole sulfide is a key step in the synthesis of rabeprazole, a drug for the treatment of stomach acid-related disorders. The current rabeprazole production process adopts one pot batch process, which has low reaction efficiency and poor stability. A continuous process can greatly improve the production efficiency and solve the above problems. Therefore, the reaction parameters of rabeprazole in microreactor were explored through laboratory experiments to explore the possibility of continuous production of rabeprazole. Rabeprazole sodium was synthesized by using rabeprazole thioether as a raw material and sodium hypochlorite solution as the oxidant. Oxidation, quenching, acid-base regulation and extraction were completed continuously in the microreactor. Rabeprazole solution with a purity of 98.78% (±0.13%) can be obtained continuously in 56 s, whereas intermittent production lasted for at least 2 h. Thus, the microreactor can effectively improve the oxidation synthesis efficiency of rabeprazole, and provide reference for the realization of other reactions in the microreactor. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Category: imidazoles-derivatives).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma was written by Nakamura, Nobuhiko;Kasahara, Senji;Kitagawa, Junichi;Nakamura, Hiroshi;Sawada, Michio;Fukuno, Kenji;Shibata, Yuhei;Kaneda, Yuto;Hara, Takeshi;Kanemura, Nobuhiro;Tsurumi, Hisashi;Shimizu, Masahito. And the article was included in Experimental Hematology & Oncology in 2022.Reference of 16506-27-7 The following contents are mentioned in the article:

This phase II clin. trial aimed to evaluate the efficacy and safety of the combination therapy of bendamustine, cytarabine, and rituximab (BRAC) in patients with relapsed or refractory follicular lymphoma (FL) or mantle cell lymphoma (MCL). Thirteen patients were enrolled and received a median of 4 cycles (range 2-6) of BRAC. The complete response rate was 61.5%, and the overall response rate was 84.6%; the 2-yr overall survival was 76.9%, and the 2-yr progression-free survival was 69.2%. Although all patients received G-CSF prophylaxis, grade 3 or higher neutropenia was observed in all cycles, and the incidence of febrile neutropenia was 20%. Grade 4 thrombocytopenia was observed in 92.5% of all cycles, and platelet transfusion was performed in 94%. Although hematol. toxicity was relatively high, BRAC therapy was effective for relapsed and refractory FL or MCL. Further studies are needed to determine the optimal dose of BRAC therapy. Trial registration The UMIN Clin. Trials Registry, UMIN000009797. Registered 17 Jan. 2013, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000011103. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Reference of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Bendamustine: a review of pharmacology, clinical use and immunological effects (review) was written by Lalic, Hrvoje;Aurer, Igor;Batinic, Drago;Visnjic, Dora;Smoljo, Tomislav;Babic, Antonija. And the article was included in Oncology Reports in 2022.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

A review. Bendamustine is an alkylating agent classified into the group of nitrogen mustard analogs, synthesized almost sixty years ago. It was registered in former East Germany in 1971 and approved by the US Food and Drug Administration in 2008 for treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Considering its beneficial properties in the therapy of relapsed or refractory hematol. malignancies, synergistic effects with other antineoplastic agents and increasing recent reports on its immunomodulatory effects, bendamustine has once again gained its justified attention. The uniqueness of bendamustine-mediated effects should be observed keeping in mind its distinctive structure with structural similarities to both alkylating agents and purine analogs. In the present review, the current knowledge on the use of bendamustine in oncol., its pharmacokinetics, mechanism of action and toxicity was summarized. In addition, its immune-modulating effects that have not been fully elucidated so far are emphasized, hoping to encourage further investigations of this unique drug. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Safety of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study was written by Allsup, David;Howard, Dena;Emmerson, Jake;Hockaday, Anna;Rawstron, Andy;Oughton, Jamie B.;Bloor, Adrian;Phillips, David;Nathwani, Amit;Paneesha, Shankara;Turner, Deborah;Munir, Talha;Hillmen, Peter. And the article was included in British Journal of Haematology in 2021.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

This study designed a COSMIC phase II randomized controlled trial (RCT) in relapsed chronic lymphocytic leukemia (CLL) to test whether high dose ofatumumab based chemoimmunotherapy (CIT) was sufficiently efficacious to be investigated in larger trials. Ofatumumab was given in combination with investigators choice of chemotherapy comprising six cycles of either fludarabine and cyclophosphamide (FC) or bendamustine (B). The treatment schedule for sOf-FC/B was FC or B in combination with ofatumumab 300 mg day 1 cycle 1, ofatumumab 1000 mg day 8 Cycle 1, ofatumumab 1000 mg day 1 cycles 2-6 and treatment schedule for megaOf-FC/B was FC or B in combination with ofatumumab 300 mg day 1 cycle 1, ofatumumab 2000 mg, days 8, 15, 22 cycle 1, ofatumumab 2000 mg days 1, 8, 15, 22 cycle 2, ofatumumab 2000 mg day 1 cycles 3-6. Observed toxicities were compatible with those known for FC, B and ofatumumab with no excess infusional reactions in megaOf treated participants. Neither sOf or megaOf in combination with FC or B, reached pre-specified endpoints in terms of rates of CR/CRi to warrant further investigation. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma was written by Lee, Hans C.;Feng, Lei;Oriabure, Onyeka;Graham, Vivian;Chen, Wendy;Badillo, Maria;Lu, Rebecca;Lee, Hun J.;Jain, Preetesh;Manasanch, Elisabet E.;Orlowski, Robert Z.;Wang, Michael L.. And the article was included in American Journal of Hematology in 2021.Recommanded Product: 16506-27-7 The following contents are mentioned in the article:

The incorporation of novel agents including immunomodulatory drugs(IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs) to myeloma treatment regimens have led to substantial gains in overall survival in patients with multiple myeloma over the last 10-15 years. However, alkylating agents remain an important option in the myeloma therapeutic armamentarium, and their use in combination with novel agents have shown to be an effective treatment strategy for both newly diagnosed and relapsed and/or refractory myeloma patients. The primary endpoint of the study was to determine the MTD of carfilzomib, bendamustine and dexamethasone with dose-limiting toxicities (DLTs) assessed during the cycle one (28-day) DLT-evaluable period. In summary, we establish the MTD of the combination of carfilzomib, bendamustine, and dexamethasone in RRMM and demonstrate its encouraging preliminary efficacy in this phase one study. These data suggest that carfilzomib in combination with the alkylating agent bendamustine may be a useful and relevant treatment option in this patient population. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Recommanded Product: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Gastroprotective delivery of rabeprazole sodium along with metoclopramide hydrochloride using treated agar was written by Ratnakar, Raikar Prasiddhi;Pankaj, Gajare;Santoshi, Naik. And the article was included in International Journal of Pharmacy and Biological Sciences in 2021.Synthetic Route of C18H20N3NaO3S The following contents are mentioned in the article:

Particle engineering is a technique of phys. modification of the excipient at sub-particle level without altering chem. properties to achieve desired functionality. For development of immediate layer of Metoclopramide Hydrochloride Treated Agar was used as disintegrating agent and was compared with untreated agar. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Synthetic Route of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Synthetic Route of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Multiple widespread fixed drug eruption caused by rabeprazole. was written by Gupta, S;Gupta, S;Mahendra, A;Yadav, A. And the article was included in Journal of postgraduate medicine in 2020.HPLC of Formula: 117976-90-6 The following contents are mentioned in the article:

Fixed drug eruption is one of the most common forms of cutaneous adverse drug reactions. Analgesics and antibiotics are the most common drugs causing fixed drug eruption. Here, we report a case of multiple widespread fixed drug eruption caused by rabeprazole. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6HPLC of Formula: 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.HPLC of Formula: 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease was written by Perez-Lamas, Lucia;Moreno-Jimenez, Gemma;Tenorio-Nunez, Maria C.;Velazquez-Kennedy, Kyra;Jimenez-Chillon, Carlos;Astibia-Mahillo, Beatriz;Nunez-Torron, Claudia;Garcia-Gutierrez, Valentin;Jimenez-Martin, Ana;Valles-Carboneras, Ana;Lopez-Jimenez, Javier F.. And the article was included in American Journal of Hematology in 2021.COA of Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease, the patient was treated with prednisone 20 mg daily with improvement of the hemolytic parameters and Hb level to baseline values. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7COA of Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.COA of Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Bis(arylimidazole) Iridium Picolinate Emitters and Preferential Dipole Orientation in Films was written by Huckaba, Aron J.;Senes, Alessia;Aghazada, Sadig;Babaei, Azin;Meskers, Stefan C. J.;Zimmermann, Iwan;Schouwink, Pascal;Gasilova, Natalia;Janssen, Rene A. J.;Bolink, Henk J.;Nazeeruddin, Mohammad Khaja. And the article was included in ACS Omega in 2018.Product Details of 914306-50-6 The following contents are mentioned in the article:

The straightforward synthesis and photophys. properties of a new series of heteroleptic iridium(III) bis(2-arylimidazole) picolinate complexes are reported. Each complex has been characterized by NMR, UV-vis, cyclic voltammetry, and photoluminescent angle dependency, and the emissive properties of each are described. The preferred orientation of transition dipoles in emitter/host thin films indicated more preferred orientation than homoleptic complex Ir(ppy)₃. This study involved multiple reactions and reactants, such as 1-(2,6-Diisopropylphenyl)-2-phenyl-1H-imidazole (cas: 914306-50-6Product Details of 914306-50-6).

1-(2,6-Diisopropylphenyl)-2-phenyl-1H-imidazole (cas: 914306-50-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Product Details of 914306-50-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials was written by Morabito, Fortunato;Tripepi, Giovanni;Del Poeta, Giovanni;Mauro, Francesca Romana;Reda, Gianluigi;Sportoletti, Paolo;Laurenti, Luca;Coscia, Marta;Herishanu, Yair;Bossio, Sabrina;Varettoni, Marzia;Murru, Roberta;Chiarenza, Annalisa;Visentin, Andrea;Condoluci, Adalgisa;Moia, Riccardo;Pietrasanta, Daniela;Loseto, Giacomo;Consoli, Ugo;Scortechini, Ilaria;Rossi, Francesca Maria;Zucchetto, Antonella;Al-Janazreh, Hamdi;Vigna, Ernesto;Martino, Enrica Antonia;Cassin, Ramona;D’Arrigo, Graziella;Galimberti, Sara;Rago, Angela;Angeletti, Ilaria;Biagi, Annalisa;Del Giudice, Ilaria;Bomben, Riccardo;Neri, Antonino;Fronza, Gilberto;Monti, Paola;Menichini, Paola;Olivieri, Jacopo;Cutrona, Giovanna;Rossi, Davide;Cuneo, Antonio;Di Raimondo, Francesco;Gaidano, Gianluca;Polliack, Aaron;Trentin, Livio;Foa, Robin;Ferrarini, Manlio;Gattei, Valter;Gentile, Massimo. And the article was included in American Journal of Hematology in 2021.SDS of cas: 16506-27-7 The following contents are mentioned in the article:

However, these biomarkers’ practical prognostic relevance in the era of new drugs remains an open issue. Results investigating the clin. impact of IB in the current clin. practice mainly focused so far on relapsedresistant (RR) patients. Here, we conducted a multicenter, retrospective study to ascertain the predictive and prognostic relevance of well-known biol. and clin. indicators in 165 patients treated with IB as first-line. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7SDS of cas: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.SDS of cas: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem